e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Pulmonary circulation: clinical treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension
D. Korte, A. Rolf, W. Seeger, A. Ghofrani, R. Voswinckel (Giessen, Bad Nauheim, Germany)
Source:
Annual Congress 2013 –Pulmonary circulation: clinical treatment
Session:
Pulmonary circulation: clinical treatment
Session type:
Thematic Poster Session
Number:
4058
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Korte, A. Rolf, W. Seeger, A. Ghofrani, R. Voswinckel (Giessen, Bad Nauheim, Germany). Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension. Eur Respir J 2013; 42: Suppl. 57, 4058
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy
Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020
Year: 2021
Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010
Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension
Source: Eur Respir J 2012; 40: 1410-1419
Year: 2012
Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Challenges in the diagnosis and treatment of pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21: 313-320
Year: 2012
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary circulation
Year: 2007
The value of cardiopulmonary exercise test in assessment of the severity of pulmonary arterial hypertension patients
Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Year: 2017
Heart rate recovery in response to disease targeted therapy in pre-capillary pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Prognostic value of hemodynamics following treatment initiation in pulmonary arterial hypertension
Source: International Congress 2017 – Cardiac function assessment in pulmonary hypertension
Year: 2017
Pressure-flow relationship during exercise predicts transplant-free survival in patients with pre-capillary pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: new pathophysiological insights
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept